Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

SARS-CoV2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwanaga, Naoki, Cooper, Laura, Rong, Lijun, Beddingfield, Brandon, Crabtree, Jackelyn, Tripp, Ralph A., Qin, Xuebin, Kolls, Jay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310620/
https://www.ncbi.nlm.nih.gov/pubmed/32587964
http://dx.doi.org/10.1101/2020.06.15.152157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310620/
https://www.ncbi.nlm.nih.gov/pubmed/32587964
http://dx.doi.org/10.1101/2020.06.15.152157

Ejemplares similares